Actively Recruiting
Implementation of a Sarcopenia Clinic to Diagnose and Treat Skeletal Muscle Loss Due to COPD
Led by The Cleveland Clinic · Updated on 2025-10-30
80
Participants Needed
1
Research Sites
111 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Sarcopenia, or skeletal muscle loss, impacts up to 40% of COPD patients and is a major cause for morbidity and mortality. Despite the high clinical significance of sarcopenia in COPD, the diagnosis remains elusive because accurate measures of skeletal muscle are not tested during routine clinical care. The goal is to use evidence-based strategies to diagnose and treat sarcopenia due to COPD. The multidisciplinary team includes a pulmonologist, pharmacist, COPD nurse, and COPD coordinator. The investigators anticipate that the approach will improve clinical outcomes for COPD patients with sarcopenia as compared to standard of care visits in ambulatory COPD clinics. The investigators will determine if the approach improves skeletal muscle mass and function, and also improves clinical outcomes related to frequency of hospitalization or ED (Emergency Department) visits, COPD exacerbations, and mortality.
CONDITIONS
Official Title
Implementation of a Sarcopenia Clinic to Diagnose and Treat Skeletal Muscle Loss Due to COPD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- COPD exacerbation was the main reason for your hospital stay or a secondary diagnosis with acute respiratory failure as the main diagnosis
- You had a CT scan during your hospital stay showing low muscle mass in the chest area
- You are older than 40 years
- You have COPD confirmed by lung function tests with at least moderate airway obstruction
- You have smoked at least 10 pack years and may be a current or former smoker
You will not qualify if you...
- You have other lung diseases such as interstitial lung disease or asthma
- You are currently being evaluated for or listed for a lung transplant
- You have an active cancer
- You have serious end organ failure such as heart failure with low ejection fraction, end stage kidney disease needing dialysis, or liver cirrhosis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
Actively Recruiting
Research Team
A
Amy Attaway, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here